HISTORY OF APMI COHORTS
Examples of previous APMI cohorts:
- Including both cognitively intact older individuals at risk for Alzheimer’s Disease and patients with a full range of other primary proteinopathies of the brain including neurodegenerative diseases
- Providing an assortment of unique heterogeneous and multidimensional data
The INSIGHT-preAD cohort (INveStIGation of AlzHeimer’s PredicTors in Subjective Memory Complainers), is a monocentric French academic university-based cohort including 318 cognitively and physically normal Caucasian individuals, recruited from the community in the wider Paris area, France, aged 70 to 85 with subjective memory complaints, defined brain amyloid status, and clinical and multimodal biomarker measurements of brain activity and function repeated over time.
The main objective of this study is to explore the earliest preclinical stages of Alzheimer’s Disease, its development, and progression by examining clinical and biological markers of Alzheimer’s Disease and other influencing factors such as lifestyles, genetic risk factors, or vascular risk factors. Demographic, cognitive, functional, nutritional, biological, genetic, genomic, imaging, electrophysiological and other assessments have been performed at baseline. The primary impact of the INSIGHT-preAD study is expected to be the detailed characterization of the little-known preclinical stage of Alzheimer’s Disease by defining differential subsets of individuals according to their clinical and biomarkers profiles.
The SOCRATES cohort (Structurizing and fOllow-up of a Cohort in Routine care concerning highly well clinical phenotyped patients with Alzheimer’s disease and relaTEd disorderS) is a novel French monocentric longitudinal cohort. The primary objective is to build a multimodal database of highly well-clinically phenotyped patients with different neurodegenerative diseases to validate the new diagnostic criteria of various neurodegenerative diseases and compare the weight of different biological markers, such as MRI, cerebrospinal fluid (CSF) biomarkers, 18F-FDG-PET, in the differential diagnosis.
The cohort includes patients with Alzheimer’s Disease, essentially at a prodromal stage and with no major comorbidities; patients with other neurodegenerative diseases, particularly: Fronto-Temporal Lobar Degeneration, Lewy Body Dementia, Posterior Cortical Atrophy, Progressive Supranuclear Palsy, and Corticobasal Degeneration.
It is a community-based multi-centric suspected prodromal Alzheimer’s Disease cohort enrolled in a double-blind, randomized, placebo-controlled parallel group design (92 placebo versus 81 donepezil) using donepezil (10mg/day). All subjects underwent two brain structural MRI scans, at baseline and at the end of the trial.
It is an observational longitudinal cohort study aiming at characterizing the predictive neuroimaging markers for the early diagnosis of Alzheimer’s Disease in a population of individuals with subjective cognitive impairments (SCI). Participants were divided into two groups: 68 individuals with SCI and 73 age- and sex-matched healthy volunteers.